Tofacitinib for juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of juvenile idiopathic arthritis (JIA), confirmed by your rheumatologist.
- Your doctor must have decided that tofacitinib is a medically appropriate treatment for your JIA.
- You must be under 18 years old at the time tofacitinib treatment was started.
- You cannot have reactive arthritis, arthritis linked to inflammatory bowel disease, or arthritis linked to another autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets young people who benefited from filgotinib (a medication that reduces inflammation) in a previous trial continue taking it to see if it stays safe and effective over a longer period. It's designed for patients ages 8–17 who did well on this medicine before.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
This study tests different medication sequences for children and teens with polyarticular juvenile idiopathic arthritis (JIA) who still have moderate or high disease activity after at least 3 months on their first tumor necrosis factor inhibitor (TNFi) therapy. The goal is to find the best next step to control symptoms and improve quality of life.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
Hear when a new Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.